Digirad Corporation (Nasdaq: DRAD; DRADP) (“Digirad” or the
“Company”), a diversified holding company with three divisions:
Healthcare, Building & Construction, and Real Estate &
Investments, announced today that KBS Builders, Inc. (“KBS”) has
partially re-opened its Oxford, Maine plant to manufacture wall
panels for the New England market, creating a new business line for
KBS. Also, KBS is studying ways to increase its modular
manufacturing output capability in 2021. Our new website was
launched yesterday at www.kbsbuildersinc.com with updated content
on the rationale for modular construction, a gallery of recent
projects, as well as improved functionality for requesting a plant
tour and contacting our sales team.
The Oxford plant, an approximately 90,000 sq.
ft. facility, was idle when it was purchased by Digirad Corporation
in April 2019. One of the ancillary buildings at this plant was
recently retrofitted and upgraded in order to be able to produce
structural wall panels. Panelized wall assemblies standardize the
construction process and give contractors cost predictability and a
higher level of project control versus on-site construction.
Production of structural wall panels for multiple clients commenced
at this plant in September and deliveries are scheduled to be
completed before year-end. EdgeBuilder, KBS's sister company and a
leading manufacturer of wall panels for the upper Midwest, provided
design support and operational oversight for these projects.
Waypoint General Contracting, a full scope
property services company, is one of the clients that contracted
with KBS for structural wall panels. Kieran McAllen, Principal at
Waypoint General Contracting, said, "We are excited to partner with
KBS and leverage their manufacturing expertise and exterior wall
panel assembly for our upcoming development projects. KBS's wall
panel manufacturing process and production system reduces the
overall build cycle, creates schedule predictability, and
significantly lowers the need for on-site, skilled labor.”
Regarding its traditional business of
manufacturing building modules, KBS continues to have a sales
pipeline exceeding $50 million. Production capacity at its South
Paris, Maine plant is sold out for the rest of this year and
bookings are starting to be made for 2021. KBS is exploring ways to
increase its modular manufacturing output in 2021, including
expanding its South Paris plant and fully re-opening its Oxford
plant. The main building at the Oxford plant is capable of
manufacturing a similar number of building modules per week as
KBS’s South Paris factory. KBS’s goal is to expand its production
capacity to 15-20 modules per week at some point in 2021, equating
to an annualized rate of 750-1000 modules per year compared to
KBS’s actual production for 2019 of approximately 230 building
modules.
Jeff Eberwein, Digirad’s Chairman, noted, “With
the re-opening of the Oxford plant, KBS entered the structural wall
panel manufacturing business in New England, adding a new line of
business for KBS. We believe KBS’s entrance into the structural
wall panel business will lead to new business opportunities in
commercial construction for our modular manufacturing operations.
In addition, given KBS’s growing backlog and sizeable sales
pipeline for full building modules at our South Paris plant, we are
excited to serve our growing list of customers by expanding our
production capability in 2021.”
Additionally, the Company’s Building &
Construction businesses recently launched new websites to improve
the user experience and drive further sales activity. Links to the
websites can be found below.
KBS Builders, Inc. www.kbsbuildersinc.com
EdgeBuilder, Inc.
www.edgebuilderwallpanels.com
Glenbrook Building Supply, Inc.
www.glenbrooklumber.com
About Digirad
CorporationDigirad Corporation is a diversified
holding company with three divisions: Healthcare, Building &
Construction, and Real Estate & Investments.
Healthcare Division
(Digirad Health)Digirad
Health designs, manufactures, and distributes diagnostic medical
imaging products and services. Digirad Health operates in three
businesses: Diagnostic Imaging, Diagnostic Services, and
Mobile Healthcare. The Diagnostic Imaging business designs,
manufactures, and sells proprietary solid-state gamma cameras. It
also services the installed base of these proprietary cameras. The
Diagnostic Services business offers imaging and monitoring services
to healthcare providers as an alternative to purchasing equipment
or outsourcing procedures. The Mobile Healthcare business
provides contract diagnostic imaging, including computerized
tomography (“CT”), magnetic resonance imaging (“MRI”), positron
emission tomography (“PET”), PET/CT, and nuclear medicine and
healthcare expertise through a convenient, mobile service.
Building & Construction Division
(ATRM)ATRM Holdings, Inc. (“ATRM”) manufactures modular
housing units for commercial and residential real estate projects.
ATRM operates in two businesses: (i) modular building manufacturing
and (ii) structural wall panel and wood foundation manufacturing,
including building supply retail operations. The modular building
manufacturing business is operated by KBS Builders, Inc. (“KBS”),
the structural wall panel and wood foundation manufacturing segment
is operated by EdgeBuilder, Inc. (“EdgeBuilder”), and the retail
building supplies are sold through Glenbrook Building Supply, Inc.
(“Glenbrook”). KBS, EdgeBuilder, and Glenbrook are all wholly-owned
subsidiaries of ATRM, which is a wholly-owned subsidiary of
Digirad.
Real Estate & Investments
DivisionThis business division manages the Company’s real
estate assets and investments.
Forward-Looking Statements Disclaimer
Statement“Safe Harbor” Statement under the Private
Securities Litigation Reform Act of 1995: This release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements in this
release that are not statements of historical fact are hereby
identified as “forward-looking statements” for the purpose of the
safe harbor provided by Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. Forward-looking Statements include, without limitation,
statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to
acquisitions and related integration, development of commercially
viable products, novel technologies, and modern applicable
services, (ii) projections of income (including income/loss),
EBITDA, earnings (including earnings/loss) per share, free cash
flow (FCF), capital expenditures, cost reductions, capital
structure or other financial items, (iii) the future financial
performance of Digirad Corporation or acquisition targets and (iv)
the assumptions underlying or relating to any statement described
above. Moreover, forward-looking statements necessarily involve
assumptions on the Company’s part. These forward-looking statements
generally are identified by the words “believe”, “expect”,
“anticipate”, “estimate”, “project”, “intend”, “plan”, “should”,
“may”, “will”, “would”, “will be”, “will continue” or similar
expressions. Such forward-looking statements are not meant to
predict or guarantee actual results, performance, events or
circumstances and may not be realized because they are based upon
the Company's current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which the
Company has no control over. Actual results and the timing of
certain events and circumstances may differ materially from those
described above as a result of these risks and uncertainties.
Factors that may influence or contribute to the inaccuracy of
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, the substantial amount of debt of the Company and the
Company’s ability to repay or refinance it or incur additional debt
in the future; the Company’s need for a significant amount of cash
to service and repay the debt and to pay dividends on the Company’s
preferred stock; the restrictions contained in the debt agreements
that limit the discretion of management in operating the business;
legal, regulatory, political and economic risks in markets and
public health crises that reduce economic activity and cause
restrictions on operations (including the recent coronavirus
COVID-19 outbreak); the length of time associated with servicing
customers; losses of significant contracts or failure to get
potential contracts being discussed; disruptions in the
relationship with third party vendors; accounts receivable
turnover; insufficient cash flows and resulting lack of liquidity;
the Company's inability to expand the Company's business;
unfavorable changes in the extensive governmental legislation and
regulations governing healthcare providers and the provision of
healthcare services and the competitive impact of such changes
(including unfavorable changes to reimbursement policies); high
costs of regulatory compliance; the liability and compliance costs
regarding environmental regulations; the underlying condition of
the technology support industry; the lack of product
diversification; development and introduction of new technologies
and intense competition in the healthcare industry; existing or
increased competition; risks to the price and volatility of the
Company’s common stock and preferred stock; stock volatility and in
liquidity; risks to preferred stockholders of not receiving
dividends and risks to the Company’s ability to pursue growth
opportunities if the Company continues to pay dividends according
to the terms of the Company’s preferred stock; the Company’s
ability to execute on its business strategy (including any cost
reduction plans); the Company’s failure to realize expected
benefits of restructuring and cost-cutting actions; the Company’s
ability to preserve and monetize its net operating losses; risks
associated with the Company’s possible pursuit of acquisitions; the
Company’s ability to consummate successful acquisitions and execute
related integration, including to successfully integrate ATRM’s
operations and realize the synergies from the acquisition of ATRM,
as well as factors related to the Company’s business (including
ATRM) including economic and financial market conditions generally
and economic conditions in the Company’s markets; failure to keep
pace with evolving technologies and difficulties integrating
technologies; system failures; losses of key management personnel
and the inability to attract and retain highly qualified management
and personnel in the future; and the continued demand for and
market acceptance of the Company’s services. For a detailed
discussion of cautionary statements and risks that may affect the
Company’s future results of operations and financial results,
please refer to the Company’s filings with the Securities and
Exchange Commission, including, but not limited to, the risk
factors in the Company’s most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q. This release reflects management’s
views as of the date presented.
All forward-looking statements are necessarily
only estimates of future results, and there can be no assurance
that actual results will not differ materially from expectations,
and, therefore, you are cautioned not to place undue reliance on
such statements. Further, any forward-looking statement speaks only
as of the date on which it is made, and we undertake no obligation
to update any forward-looking statement to reflect events or
circumstances after the date on which the statement is made or to
reflect the occurrence of unanticipated events.
For more information contact: |
Digirad Corporation |
|
The Equity Group |
Jeffrey E. Eberwein |
|
Lena Cati |
Chairman of the Board |
|
The Equity Group |
203-489-9501 |
|
212-836-9611 |
ir@digirad.com |
|
lcati@equityny.com |
Digirad (NASDAQ:DRAD)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Digirad (NASDAQ:DRAD)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024